GF 2010
Alternative Names: GF-2010Latest Information Update: 09 Aug 2022
At a glance
- Originator GenFleet Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 01 Aug 2022 Preclinical trials in Solid tumours in China (Parenteral) (GenFleet Therapeutics pipeline, August 2022)